التفاصيل البيبلوغرافية
| العنوان: |
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand. |
| المصدر: |
Pharma Business Week; 4/5/2024, p385-385, 1p |
| مصطلحات موضوعية: |
EXCLUSIVE contracts, LICENSE agreements, DRUGS, NEUROLOGICAL disorders, SENSORY disorders, HEALTH boards |
| مصطلحات جغرافية: |
NEW Zealand |
| مستخلص: |
Fennec Pharmaceuticals and Norgine have entered into an exclusive licensing agreement for the commercialization of PEDMARQSI in Europe, Australia, and New Zealand. PEDMARQSI is the first approved therapy in the EU and UK for the prevention of hearing loss induced by cisplatin chemotherapy in pediatric patients with localized, non-metastatic solid tumors. Under the agreement, Fennec will receive upfront consideration and milestone payments, while Norgine will be responsible for commercialization activities. The therapy has been granted marketing authorization in Europe and the UK based on safety and efficacy data from two Phase 3 trials. [Extracted from the article] |
|
Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
